Purchase Order 75N90021P00365

<p>The NIH Clinical Center awarded a purchase order to Cellgenix USA for $16,860 on July 6, 2020. The order procures GMP SCF (50 micrograms), GMP FLT-3L (50 micrograms), and GMP TPO (50 micrograms)—specialized cytokine reagents for cell and gene therapy research. Place of performance is Portsmouth, New Hampshire. Ultimate completion date is July 20, 2020. No set-aside applied to this firm fixed-price acquisition.</p>

<p>The NIH Clinical Center awarded a purchase order to Cellgenix USA for $11,942.50 on August 4, 2020, for CellGenix RH TPO GMP and preclinical grade materials and GMP FLT-3L (50 micrograms). The order is firm fixed price with no set-aside designation. Work is performed in Portsmouth, New Hampshire, with an ultimate completion date of August 11, 2020.</p>

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $103,103.00 firm fixed-price purchase order contract to Cellgenix USA, a division of Cellgenix GMBH, a for-profit manufacturer of goods. The contract, which had no set-aside designation, is for the provision of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, interleukin-4, and other cell therapy reagents to support federal cell and gene therapy research...

The National Institutes of Health (NIH) Clinical Center awarded a Firm Fixed Price Purchase Order contract worth $138,390.00 to Cellgenix USA, a division of Cellgenix GMBH. The contract is for the delivery of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, and interleukin-4 to support cell and gene therapy research and development at the NIH. Cellgenix USA has provided similar products to the NIH and the National Institute of Allergy and Infectious Diseases...

<p>The NIH Clinical Center awarded a purchase order to Cellgenix USA for $26,780 on January 12, 2018, with completion by February 12, 2018. No set-aside applied. Performance occurs in Bethesda, Maryland. The order procures specialized pharmaceuticals for cell and gene therapy research, including cytokines, growth factors, and related reagents to support NIH research initiatives. The contract carries firm fixed-price pricing.</p>

<p>The National Institutes of Health Clinical Center issued a purchase order to Cellgenix USA for $23,182.50 on February 5, 2020, for human interleukin 4 for use in NIH protocols. The order carries a firm fixed price and concludes on February 14, 2020. Place of performance is Portsmouth, New Hampshire.</p>

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. valued at $28,950.76 on March 24, 2020, with ultimate completion on April 24, 2020. Performance takes place in Bethesda, Maryland. The order is for advanced biological research products and laboratory supplies, including cell isolation kits, cell culture media, cell separation systems, and research-grade reagents to support biomedical research. No small business set-aside was used.</p>

<p>The NIH Clinical Center awarded a purchase order to Stemcell Technologies Inc. valued at $28,950.76 on March 25, 2020, for advanced biological research products and laboratory supplies. Work is performed in Bethesda, Maryland. The order carried firm fixed-price pricing with an ultimate completion date of April 30, 2020. No set-aside was used.</p>

The NIH Clinical Center awarded a purchase order to Miltenyi Biotec, Inc. valued at $20,493.00 on November 22, 2017, with completion by November 30, 2017. The order is firm fixed price with no set-aside. Place of performance is Bethesda, Maryland. The purchase order procures specialized biotechnology equipment, reagents, and consumables for cell separation, analysis, and processing—including proprietary cell isolation microbeads, isolation kits, and tubing sets that support cell therapy...

<p>The NIH Clinical Center awarded a purchase order to Sirion Biotech GMBH valued at $21,966.56 on January 28, 2019. Performance is located in Germany with an ultimate completion date of February 19, 2019. The order is for LENTIBOOST formulated, GMP-grade lentiviral viral vector products to support gene therapy research. Pricing is firm fixed price with no small business set-aside applied.</p>